VenoStent, Inc.’s Post

Parent Project Muscular Dystrophy’s mission has always been clear: to fight Duchenne by putting patients at the heart of every research effort. By leveraging CTTI’s Patient Group Engagement recommendations, particularly their “Chevron Diagram,” they’ve been able to amplify the patient voice throughout the entire drug development process. From discovery to post-approval, patient preference studies now play a crucial role in shaping research priorities and clinical trial designs. The results? Seven patient preference studies completed to date, providing critical insights that are guiding decisions at every stage. Learn more about how together we’re building a research ecosystem that values patient insights and fosters meaningful collaboration. https://bit.ly/PPMDcs

On #LimbGirdleAwarenessDay, we’re proud to announce the launch of C-Path’s new task force dedicated to advancing drug development for limb-girdle muscular dystrophies. Under the Rare Disease Cures Accelerator-Data and Analytics Platform, this collaborative effort unites experts from leading organizations to tackle the unmet medical needs in the LGMD community. This task force includes pivotal members: ML Bio Solutions (BridgeBio), Coalition to Cure Calpain 3, CURE LGMD2I FOUNDATION, Jain Foundation Inc, LGMD2D Foundation, LGMD2i Research Fund and The Speak Foundation. Together, we’re leveraging patient-level data, shared knowledge, and a neutral platform to expedite therapeutic advancements for those affected by LGMDs. As we work toward accelerating meaningful progress, our commitment remains to ensure patient voices and data drive innovation. Read the full details, here: https://lnkd.in/gFiffMB3 Alexandre Bétourné, PhD, PharmD, PMP Heidi Grabenstatter Douglas Sproule Kat Bryant Knudson Ramona Belfiore-Oshan Rachel DeConti Adora Ndu, PharmD, JD Anna Wade Cybele Gouverneur Jean-Pierre Laurent Jennifer Levy Jessica Evans Kelly Brazzo Laura Rufibach Patrick Moeschen #CPath #LimbGirdleMuscularDystrophy #RareDiseaseResearch #DataCollaboration #DrugDevelopment #DataSharing #RDCADAP #PatientVoice #Collaboration

Catch Richie Pfeiffer presenting at the #Lupus Clinical Investigators Network (LuCIN) meeting in San Diego, where he will be looking at the role decentralized clinical trials play to increase #diversity and representation in lupus research. Learn more about our work this #LupusAwarenessMonth. » https://bit.ly/3y1OX2W #decentralizedclinicaltrials #clinicalresearch #lupusresearch

Yesterday, our CEO, Frederic Cren; CMO, Dr. Michael Cooreman; and Dr. Stephen Harrison, Medical Director for Pinnacle Clinical Research, shared key insights on the latest developments of lanifibranor in #MASH/ #NASH treatment. Learn more about the positive results of LEGEND Phase IIa combination trial with #lanifibranor and empagliflozin for MASH/NASH and #T2D patients: https://lnkd.in/ejxiZj6s

We're presenting three abstracts at #ARVO2024! The Exonate team will be presenting our exciting #clinicaltrial data from the recent Phase Ib/IIa mild NPDR/DME (NCT04565756) clinical study which assessed the safety, tolerability and signals of biological response to EXN407, as well as a digital strategy for #patient enrolment, and additional information on our lead candidate EXN407. More information below ⬇ #Ophthalmology #MacularEdema

The transformation of healthcare and the drive to enhance patient care can only be achieved through strong partnerships. The shared mission of Velatura Public Benefit Corporation & Spesana is changing the continuum of care for clinicians and patients. Improved prior authorization means faster time to diagnosis and faster time to treatment. #partnerships  #precisionmedicine  #priorauthorization  #healthcare #transformation  #hie #interoperability  #patientcare  #moleculardiagnostics

The transformation of healthcare and the drive to enhance patient care can only be achieved through strong partnerships. The shared mission of Velatura Public Benefit Corporation & Spesana is changing the continuum of care for clinicians and patients. Improved prior authorization means faster time to diagnosis and faster time to treatment. #partnerships #precisionmedicine #priorauthorization #healthcare #transformation #hie #interoperability #patientcare #moleculardiagnostics

For more information on this Oral Abstract where GOG-3059 will be presented during the 2024 ASCO Annual Meeting, go to https://ow.ly/4QV050S0FhW or click in bio. #clinicaltrials #GOGF #GOGPartners #GynecologicOncology #ASCO24

The therapeutic window for anti-CTLA-4 therapy has been an outstanding challenge for so many years including most first and second generation anti-ctla-4 therapies! The therapeutic window is well reflected by the RP2D used in combination with anti-PD-1; for example, if NO premedication such as steroid or anti-IL6 or anti-TNFa etc is used, few second generation anti-CTLA-4 therapies in combination with anti-PD1/PD-L1 has go beyond RP2D used by ipilimumab or tremelimumab, the first generation anti-CTLA-4 therapies receiving FDA approval. For reference, ipi is dosed at 1 mpk (~75 mg in flat dose) q6w continuously or 3 mpk (~225 mg in flat dose) for up to 4 cycles in combination with nivolumab. An unprecedented improvement in therapeutic window for ADG126, anti-CTLA-4 SAFEbody, enables us to dose it at 10 mpk Q3/6W continuously (>4 cycles) in combination with Pembro to unleash therapeutic efficacy in advanced MSS CRC pts where Pembro monotherapy has minimal efficacy...

📣 Dive Deeper into STING & TLR Innovations! 🚀 Missed our recent webinar, "Harnessing STING & TLR: Current Developments, Clinical Trials, and Key Players in the Landscape"? Don't worry, you can still catch up! Watch the session on demand to explore the latest advancements in the STING & TLR pipeline, discover new combination therapies, and dive into innovative strategies shaping the future of treatment. 🔗 Watch Now: https://ter.li/z3x8at Stay informed and ahead in the dynamic field of STING & TLR-targeted therapies! #ImmunoOncology #STING #TLR #Checkpoint